Literature DB >> 3838755

63Ni electron-capture gas chromatographic assay for buprenorphine and metabolites in human urine and feces.

E J Cone, C W Gorodetzky, D Yousefnejad, W D Darwin.   

Abstract

A 63Ni electron-capture gas chromatographic assay is described for buprenorphine, a potent narcotic agonist--antagonist. In addition, the assay is useful for the measurement of the metabolite norbuprenorphine and demethoxybuprenorphine, a rearrangement product resulting when buprenorphine is exposed to acid and heat. An extraction procedure was developed which optimized recovery of buprenorphine from biological samples and produced minimal background interferences and emulsion problems. Extract residues were derivatized with pentafluoropropionic anhydride and assayed by gas chromatography. Samples were analyzed with and without enzyme hydrolysis, thus providing a selective and sensitive assay for both free and conjugated buprenorphine, norbuprenorphine and demethoxybuprenorphine. The lower limits of detection following extraction of a 1-ml sample were ca. 10 ng/ml for buprenorphine and demethoxybuprenorphine and 5 ng/ml for norbuprenorphine. Application of the assay to human samples following a 40-mg oral dose of buprenorphine produced no evidence for the presence of demethoxybuprenorphine in urine or feces. Norbuprenorphine (free and conjugated) was present in urinary and fecal samples; buprenorphine (free and conjugated) was found in high amounts only in feces and in trace amounts in urine as conjugated buprenorphine. The urinary and fecal excretion pattern observed for a human subject following oral dosing of buprenorphine suggests enterohepatic circulation of buprenorphine.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3838755     DOI: 10.1016/0378-4347(85)80042-6

Source DB:  PubMed          Journal:  J Chromatogr


  8 in total

Review 1.  Interpretation of oral fluid tests for drugs of abuse.

Authors:  Edward J Cone; Marilyn A Huestis
Journal:  Ann N Y Acad Sci       Date:  2007-03-01       Impact factor: 5.691

2.  Validation and application of a method for the determination of buprenorphine, norbuprenorphine, and their glucuronide conjugates in human meconium.

Authors:  Sherri L Kacinko; Diaa M Shakleya; Marilyn A Huestis
Journal:  Anal Chem       Date:  2007-11-29       Impact factor: 6.986

3.  Urinary excretion of buprenorphine, norbuprenorphine, buprenorphine-glucuronide, and norbuprenorphine-glucuronide in pregnant women receiving buprenorphine maintenance treatment.

Authors:  Sherri L Kacinko; Hendree E Jones; Rolley E Johnson; Robin E Choo; Marta Concheiro-Guisan; Marilyn A Huestis
Journal:  Clin Chem       Date:  2009-03-26       Impact factor: 8.327

4.  Investigation of the antinociceptive activity of buprenorphine in sheep.

Authors:  A Nolan; A Livingston; A E Waterman
Journal:  Br J Pharmacol       Date:  1987-11       Impact factor: 8.739

5.  Reassessment of buprenorphine in conditioned place preference: temporal and pharmacological considerations.

Authors:  Thomas M Tzschentke
Journal:  Psychopharmacology (Berl)       Date:  2003-11-13       Impact factor: 4.530

6.  Simultaneous quantification of buprenorphine, norbuprenorphine, buprenorphine glucuronide, and norbuprenorphine glucuronide in human placenta by liquid chromatography mass spectrometry.

Authors:  Marta Concheiro-Guisan; Diaa M Shakleya; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2009-02-27       Impact factor: 4.142

7.  Development and validation of a liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of buprenorphine, norbuprenorphine, and metabolites in human urine.

Authors:  Sherri L Kacinko; Marta Concheiro-Guisan; Diaa M Shakleya; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2008-08-30       Impact factor: 4.142

8.  Voriconazole greatly increases the exposure to oral buprenorphine.

Authors:  Mari Fihlman; Tuija Hemmilä; Nora M Hagelberg; Janne T Backman; Jouko Laitila; Kari Laine; Pertti J Neuvonen; Klaus T Olkkola; Teijo I Saari
Journal:  Eur J Clin Pharmacol       Date:  2018-08-30       Impact factor: 2.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.